In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.
The group led by U.S. Representative Richard Hudson and Herbert Conaway wrote the letter urging immediate action against the rising threat of illegal, counterfeit anti-obesity medications entering the U.S.
